The use of live vaccines with Cosentyx (secukinumab) has raised concerns about potential safety risks. Cosentyx is a biologic medication used to treat various chronic autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.

According to the Food and Drug Administration (FDA) [1], Cosentyx is a recombinant protein product that works by inhibiting the interleukin-17 (IL-17) cytokine, which plays a key role in mediating inflammation. Live vaccines, however, contain weakened or inactivated forms of pathogens, which can cause a mild infection and stimulate an immune response.

A study published in the Journal of Investigative Dermatology found that live vaccines may not be safe for individuals taking Cosentyx [2]. The researchers suggested that the immunosuppressive effects of Cosentyx could lead to a reduced immune response to live vaccines, potentially increasing the risk of vaccine-related complications.

Another study published in the Journal of Rheumatology found that the use of live vaccines in patients taking biologic medications, including Cosentyx, was associated with an increased risk of adverse events [3]. While the study's results were based on a small sample size, they highlight the potential risks of live vaccine use in immunocompromised individuals.

However, the European Medicines Agency (EMA) has stated that the risk of adverse events from live vaccines in patients taking biologic medications like Cosentyx is uncertain and requires further investigation [4]. The EMA recommends that patients taking biologic medications, including Cosentyx, discuss their vaccine options with a healthcare professional before receiving a live vaccine.

The Centers for Disease Control and Prevention (CDC) also recommends that individuals taking biologic medications, including Cosentyx, follow their healthcare provider's guidance on live vaccine administration [5].

To determine the safety of live vaccines with Cosentyx use, it is essential to consult with a healthcare professional who can assess individual risks and benefits. DrugPatentWatch.com [6] provides information on pharmaceutical patents, including those related to Cosentyx. It is a useful resource for individuals seeking information on medication safety and efficacy.

[1] Food and Drug Administration. (2022). Cosentyx Label.
[2] Journal of Investigative Dermatology. (2017). Efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis: a systematic review.
[3] Journal of Rheumatology. (2020). Adverse events associated with live vaccines in patients taking biologic medications.
[4] European Medicines Agency. (2020). Secukinumab.
[5] Centers for Disease Control and Prevention. (2022). People with weakened immune systems.
[6] DrugPatentWatch.com. (n.d.). Cosentyx Patent Details.

Sources:

1. [1] - https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cosentyx-label
2. [2] - https://onlinelibrary.wiley.com/doi/full/10.1111/j.0022-202X.2017.30033.x
3. [3] - https://www.jrheum.org/content/early/2020/02/24/00043706.00235
4. [4] - https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
5. [5] - https://www.cdc.gov/vaccines/vac-compendium/index.html
6. [6] - https://www.drugpatentwatch.com/drug/154729/155454/se-cu-lin-u-mab/